top of page
header-slider-1-1024x391.jpg
picto-asthme-blanc.png

Hephaï, the application that supports patients in correct inhaler use

Did you know that an estimated 30 to 40% of patients with asthma or COPD don’t know how to use their inhaler correctly? 

 

Almost 300 million people worldwide live with asthma or COPD. 

 

Hephaï is developing a unique application to help patients correctly use their inhalers prescribed for asthma and COPD. 

Soufle.PNG
picto-hephai-bleu.png

Hephaï, a unique application
to support correct inhaler use

_____

Correctly using an inhaler can be surprisingly difficult. It requires a degree of dexterity and a series of potentially complicated movements. The medical consequences of a patient failing to use their inhaler correctly (misuse), are far significant, as it means the disease is not properly managed.  

 

Hephaï is a unique application designed to help patients use inhalers prescribed for asthma and COPD (Chronic Obstructive Pulmonary Disease) correctly, using a virtual coach

 

Hephaï’s goal is to improve the management of chronic diseases by minimizing the medical risks associated with misuse. 

Partners
_____

Micosoft.png
AP-HP.gif
Vizua.png
téléchargement.png
logopbs96.png
France-Biotech-logo.png
jkkjmssdsdsdsss-1.png
unnamed.png
logo_chiesi.png
L'application Hephaï expliquée
picto-poumons-blanc.png

The Hephaï Application Explained
__

02

How does it work?

picto-mobile-bleu.png

03

picto-loupe-bleu.png

About asthma and COPD

Team

Valéry Trosini-Desert Hephaï.jpeg
Serge.PNG
Thomas.PNG

Dr Valéry Trosini-Désert

 

Founder

_

Chief Scientific Officer

Pneumologist 

Serge Kinkingnéhun

 

CEO

_

EyeBrain, ICM, HEC Paris

Mines Saint-Etienne

Pr Thomas Similowski

 

Scientific committee chair

_

Armelle Roussac

 

Head of sales

Equipe
Actualités
Capture d’écran 2022-09-14 à 18.04.31.png
picto-bulles-bleu.png

News
______

3 QUESTIONS TO ARMELLE ROUSSAC, HEAD OF SALES_ 09.2022

____

This appointment reinforces Hephaï leadership team as it prepares for CE marking of its application and partners with major pharmaceutical groups to make app available for asthma and COPD patients by end of 2022 

HEPHAï APPOINTS ARMELLE ROUSSAC AS HEAD OF SALES_ 06.2022

____

This appointment reinforces Hephaï leadership team as it prepares for CE marking of its application and partners with major pharmaceutical groups to make app available for asthma and COPD patients by end of 2022 

HEPHAï APPOINTS ARMELLE ROUSSAC AS HEAD OF SALES_ 06.2022

____

This appointment reinforces Hephaï leadership team as it prepares for CE marking of its application and partners with major pharmaceutical groups to make app available for asthma and COPD patients by end of 2022 

HEPHAÏ RECEIVES 2021 CATALYST AWARD FROM US NATIONAL ACADEMY OF MEDICINE_ 09.2021

____

$50k prize from US National Academy of Medicine recognizes Hephaï’s AI-based platform designed to help asthma and COPD (Chronic Obstructive Pulmonary Disease) patients

640px-Patented.jpg

HEPHAï FILES SOFTWARE PATENT FOR ITS DIGITAL EDUCATION PLATFORM_ 06.2021

____

This patent will allow Hephaï to protect its unique AI-based software for its educative platform - designed to help asthma and COPD patients avoid potential problems associated with incorrect inhaler use. 

logo_chiesi.png

HEPHAï PARTNERS WITH CHIESI _ 03.2021

____

Chiesi and Hephaï join forces to develop AI educational tool to improve inhaler use - avoiding problems arising from incorrect use. 

Contact

Contact

_____

Thanks for your message

bottom of page